July 25, 2016
Biopharma is taking steps to personalize cancer care. Cancer immunotherapies, lauded for putting the body’s own defense systems to work against cancer cells, have generated widespread excitement.
As spinoffs of cancer immunotherapies, cell therapies are gaining traction in development. “Cell therapies and immuno-oncology in general will change the face of cancer care, especially in solid tumors and high-risk hematologic malignancies,” says Dr. Andre Goy, chairman, John Theurer Cancer Center, and chief, division of lymphoma, Hackensack University Medical Center.